Scottish Medicines Consortium issues advice on five drugs
The Scottish Medicines
Consortium (SMC) has issued advice on five drugs:
· Conjugated oestrogen medroxyprogesterone (Premique Low Dose) has been
accepted as a hormone replacement therapy for oestrogen deficiency symptoms
in postmenopausal women with an intact uterus.
· Losartan (Cozaar) has been accepted for restricted use as an alternative
treatment to delay progression of renal disease and to reduce proteinuria
in patients with type 2 diabetes with nephropathy if the patient is unable
to tolerate an ACE inhibitor.
· Testosterone mucoadhesive buccal tablets (Striant) have been accepted
for restricted use as testosterone replacement therapy in men with primary
or secondary hypogonadism, but only when intramuscular treatment is not
suitable.
· Also accepted for restricted use is aprepitant (Emend). It is recommended
for prevention of acute and delayed nausea and vomiting associated with
highly emetogenic cisplatin-based chemotherapy.
· Solifenacin (Vesicare) was not recommended for treatment of urge incontinence
or increased urinary frequency. The SMC says that, although solifenacin
was effective in reducing symptoms associated with overactive bladder,
the economic case for its use was not demonstrated. |
The
Pharmaceutical Journal
Acrobat
Reader